MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, March 02, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in March 2023:

• TD Cowen’s 43^rd Annual Health Care Conference (Boston). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in the GI/GU Oncology Corporate Panel Discussion on Tuesday, March 7, 2023, at 12:50 pm ET.  MacroGenics’ management will also participate in one-on-one meetings; and
• Barclays Global Healthcare Conference (Miami). Scott Koenig, M.D., Ph.D. will participate in a fireside chat on Tuesday, March 14, 2023, at 9:30 am ET. MacroGenics’ management will also participate in one-on-one meetings.

A webcast of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm.  The Company will maintain an archived replay of these webcasts on its website for 30 days.

About MacroGenics, Inc.

MacroGenics (the Company) is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

###

You May Also Be Interested In

• Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
• Montage Gold provides exploration update at its Didievi project in Côte d’Ivoire which is poised to be its next development asset
• Revenue Growth Agent Expands AI Sales Execution Platform From Discovery Through Proposal Development